تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
0.5051 US$
−0.0999 US$ · -16.51%
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
الإغلاق السابق
0.5051 US$
−0.0999 US$ · -16.51%
قبل افتتاح السوق
0.4978 US$
−0.0073 US$ · -1.45%
13 أكتوبر، 8:18 ص ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
نطاق اليوم
السعر الحالي 0.5051 US$
نطاق 52 أسبوعًا
السعر الحالي 0.5051 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
51
قيمة عادلة
المشاعر
69
صعودي
المخاطر
45
مخاطر أعلى من المعتاد
الزخم
69
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
نطاق اليوم
السعر الحالي 0.5051 US$
نطاق 52 أسبوعًا
السعر الحالي 0.5051 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 26 فبراير 2025 | 1:15 | — | — |
ساري 26 فبراير 2025
1:15
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI1.4 مليون0.00%2.3 ترليون USD0.03%381.57 US$-0.10%
Vanguard Extended Market ETFVXF541.95 ألف0.00%95.4 مليار USD0.05%233.52 US$-0.63%
iShares Russell 2000 ETFIWM300.68 ألف0.00%78.74 مليار USD0.19%277.9 US$-0.37%
Vanguard Russell 2000 ETFVTWO234.39 ألف0.00%18 مليار USD0.06%112.27 US$-0.35%
Fidelity Enhanced Small Cap ETFFESM110.81 ألف—6.41 مليار USD0.28%45.24 US$-0.48%
iShares Micro-Cap ETFIWC38.37 ألف0.00%1.32 مليار USD0.60%181.66 US$-0.73%
Invesco NASDAQ Future Gen 200 ETFQQQS35.02 ألف0.15%22.76 مليون USD0.20%41.414 US$-1.73%
Vanguard Russell 2000 Value ETFVTWV32.35 ألف0.00%1.4 مليار USD0.06%185.97 US$+0.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Russell 2000 Value ETFVTWVالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
